LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

Geraldine Goss, Gail Darling, Virginie Westeel, K. Nakagawa, B. Massutí Sureda, Franco Perrone, S-A. McLachlan, Jin Hyoung Kang, Yi‐Long Wu, Anne‐Marie C. Dingemans, R. Dziadziuszko, M. Okada, Laurent Greillier, C. Audigier-Valette, S. Sugawara, Ernest Nadal, A. Catino, Martin R. Stockler, Kai Ding, C. O'Callaghan